ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Viral therapy"

  • 2019 American Transplant Congress

    Protocol Cidofovir for Refractory Polyomavirus Associated Nephropathy in Kidney Transplant Recipients

    J. Clark, A. Haririan

    University of Maryland Medical Center, Baltimore, MD

    *Purpose: Dose-limiting nephrotoxicity has historically precluded the use of cidofovir for polyomavirus associated nephropathy (PVAN). With incidence of BK viremia in kidney transplant recipients increasing…
  • 2018 American Transplant Congress

    Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients and Role of Prophylaxis

    G. Nance,1 A. Serluco,1 S. Deshpande,2,1 R. Garro,3,1 R. George,3,1 M. Kelleman,3 R. Liverman.1

    1Children's Healthcare of Atlanta, Atlanta, GA; 2Sibley Heart Center Cardiology, Atlanta, GA; 3Emory University, Atlanta, GA.

    Objectives: Cytomegalovirus (CMV) is an opportunistic infection that can lead to significant complications post-transplant. Purpose of this study was to evaluate the use of valganciclovir…
  • 2018 American Transplant Congress

    Val-Ganciclovir Prophylaxis Delays Onset of EBV Viremia in the First Year Post-Solid Organ Transplantation in High-Risk Patients

    S. Albatati,1 A. Sharma,2 S. Gantt,1 K. Haubrich,1 A. Wright,1 T. Blydt-Hansen.1

    1University of British Columbia, Vancouver, Canada; 2University of Manitoba, Winnipeg, Canada.

    Introduction: Donor-derived primary Epstein-Barr virus (EBV) infection poses serious risks to EBV naïve children post-solid organ transplantation, including development of EBV-related PTLD. Currently, there is…
  • 2018 American Transplant Congress

    Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus

    H. Joharji, A. Al-Jedai, D. Alkortas, A. Ajlan, E. Devol, M. Ahmed, F. Aba Al-Khail, H. El-Siesy, M. Al-Sebayel, H. Al-Ashgar, M. Al-Quaiz, W. Alhomodi, A. Aloubal, A. Almohishir.

    King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.

    Genotype 4 HCV is the most common genotype in Saudi Arabia and the Middle East. Management of genotype 4 HCV has shifted to interferon free…
  • 2018 American Transplant Congress

    Effect of Direct-Acting Hepatitis C Treatment Regimens on Calcineurin Inhibitors in Liver and Kidney Transplant Patients

    M. Laub, J. Byrns, M. Harris, C. Berg, S. Sanoff.

    Duke University Hospital, Durham, NC.

    Background: It has been suggested that treatment with direct-acting antivirals (DAA) for hepatitis C virus (HCV) may decrease calcineurin inhibitor (CNI) concentrations. The purpose of…
  • 2018 American Transplant Congress

    Building a Third-Party VST Bank from Scratch- The Cincinnati Experience

    A. S. Nelson,1 D. Heyenbruch,2 X. Zhu,3 S. M. Davies,1 C. Lutzko,3 C. Bollard,4 P. Hanley,4 T. Leemhuis,2 L. Danziger-Isakov,5 M. S. Grimley.1

    1Bone Marrow Transplant & Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; 2Hoxworth Blood Center, Univeristy of Cincinnati, Cincinnati, OH; 3Experimental Hematology & Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; 4Proram for Cell Enhancement and Technologies for Immunotherapy, Children's National Health System, Washington, DC; 5Depatment of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

    BackgroundViral infections remain a challenge to treat and significantly contribute to morbidity and mortality. Virus specific T cells (VSTs) have shown clinical efficacy, with minimal…
  • 2018 American Transplant Congress

    Prospective, Multi-Center Observational Study of Cell-Mediated Immunity for Cytomegalovirus Infection in Kidney Transplant Recipients

    D. Kumar,1 P. Chin-Hong,2 L. Kayler,3 D. Wojciechowski,4 A. Limaye,5 O. Gaber,6 S. Ball,7 A. Mehta,8 T. Blanchard,9 C. Kotton.4

    1UHN, Toronto, Canada; 2UCSF, San Francisco; 3ECMC, Buffalo; 4MGH, Boston; 5UOWMC, Seattle; 6WCMC, Houston; 7UHB, Birmingham, United Kingdom; 8EmoryU, Atlanta; 9Oxford Diag, Marlborough.

    Background:T-cell-mediated immunity (CMI) is crucial for the control of CMV infection post-transplant. We evaluated a novel EliSpot assay to determine whether CMI results could predict…
  • 2018 American Transplant Congress

    Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant

    A. Bixby, L. Fitzgerald, R. Leek, J. Mellinger, S. Tischer.

    Michigan Medicine, Ann Arbor, MI.

    Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…
  • 2018 American Transplant Congress

    Direct-Acting Antiviral Therapy Immune-Mediated Graft Dysfunction in Liver Transplant Recipients with Hepatitis C

    C. Chan,1 E. Agudelo,2 J. Haydek,3 M. Hoteit,4 M. Laurito,5 J. Norvell,3 T. Schiano,6 N. Terrault,2 E. Verna,5 A. Yang,1 J. Levitsky.1

    1Northwestern University, Chicago, IL; 2UCSF, San Francisco, CA; 3Emory University, Atl, GA; 4University of Pennsylvania, Philadelphia, PA; 5Columbia University, NY, NY; 6Mount Sinai, NY, NY.

    Background and Aims:Interferon (IFN) treatment of hepatitis C virus (HCV) infection after liver transplantation (LT) can result in severe immune-mediated graft dysfunction (IGD). The occurrence…
  • 2018 American Transplant Congress

    Incidence of Acute Cellular Rejection in Liver Transplant Patients Receiving Direct Acting Antivirals for Hepatitis C Treatment

    D. Bley,1 L. Sagardia,1 R. Ford,2 S. Todd.1

    1Pharmacy, Emory University Hospital, Atlanta, GA; 2School of Medicine, Emory University, Atlanta, GA.

    Direct acting antivirals (DAAs) have been used for the treatment of hepatitis C (HCV) in liver transplant patients since early on after their approval, however…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences